D-0017-2027 Class II Ongoing
FDA drug recall D-0017-2027 was initiated by Carolina Infusion, LLC on Sep 10, 2026 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product. The recall status is ongoing. Affected quantity: 5.6 mLs - in patient specific syringe doses.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 14, 2026
- Initiation Date
- Sep 10, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 5.6 mLs - in patient specific syringe doses
Product description
TIRZEPATIDE 26 MG/ML INJECTABLE, Packaged in single-use dosage syringes, total mL dispensed based on dosage per specific patient prescription, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936;
Reason for recall
Lack of Assurance of Sterility: Related to formulation using bacteriostic water; Related to processing equipment used in compounded product.
Distribution pattern
Nationwide within the U.S
Code information
Lots: 09012026@3, BUD: 10/16/2026; 08032026@16, BUD: 9/17/2026; 08052026@8, BUD: 9/19/2026; 08072026@13, BUD: 9/21/2026.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0017-2027
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026